期刊
INFLAMMATORY BOWEL DISEASES
卷 19, 期 13, 页码 2927-2936出版社
OXFORD UNIV PRESS INC
DOI: 10.1097/MIB.0b013e31829aad16
关键词
pediatric inflammatory bowel disease; Crohn's disease; ulcerative colitis; anti-TNF; risk; shared decision making; Option Grid
资金
- Abbott Labs
- Janssen
- UCB
- National Institute of Diabetes and Digestive and Kidney Diseases [K23DK078678]
- Agency for Healthcare Research and Quality [1R01HS021747-01]
Anti-tumor necrosis factor agents are now considered to be a vital component of the treatment algorithm for pediatric inflammatory bowel disease. Despite the clear benefit of these agents and the realignment of treatment goals to achieve early mucosal healing, the decision to initiate therapy is often delayed due to uncertainties regarding risks and benefits. The purpose of this review was to summarize the currently available data regarding anti-tumor necrosis factor agents in pediatric inflammatory bowel disease. Specifically, we review their expected efficacy in both Crohn's disease and ulcerative colitis and the likelihood of side effects associated with these agents. In addition, we address the barriers physicians face when communicating these data and help to identify how pediatric patients and their parents can be more involved in a shared decision-making process. Through the creation of a new decision aid (Option Grid), we hope to allow for a more clear line of communication at the bedside when helping patients and parents make these difficult treatment decisions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据